Abstract: A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
May 7, 2024
Assignee:
NovMetaPharma Co., Ltd.
Inventors:
Hoe Yune Jung, Heon Jong Lee, Do Hyun Lee
Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the disclosure and methods of using and producing same are also disclosed.
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Type:
Grant
Filed:
August 3, 2021
Date of Patent:
April 23, 2024
Assignee:
Genentech, Inc.
Inventors:
Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
Abstract: The present disclosure described herein provides compositions with a membrane-penetrating properties and methods for allowing translocation across a membrane without disruption.
Type:
Grant
Filed:
June 8, 2022
Date of Patent:
April 9, 2024
Assignee:
FLAGSHIP PIONEERING INNOVATIONS V, INC.
Inventors:
Laura Gabriela Lande, David Arthur Berry
Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
Inventors:
Han Remaut, Sander Van Der Verren, Nani Van Gerven, Lakmal Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, John Joseph Kilgour
Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
March 5, 2024
Assignee:
Omrix Biopharmaceuticals Ltd.
Inventors:
Israel Nur, Elena Grimberg, Itai Podoler, Inbar Gahali-Sass, Erez Ilan, Ronen Eavri
Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
Type:
Grant
Filed:
August 17, 2022
Date of Patent:
February 27, 2024
Assignee:
BicycleTx Limited
Inventors:
Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.
Abstract: Disclosed are methods of treating, inhibiting, or preventing the development of, a food allergy in a patient by administering a therapeutically effective amount of a thiol isomerase inhibitor to a patient in need thereof. Also disclosed are methods for treatment of other allergic diseases and inflammatory diseases.
Abstract: The invention relates to functionalized polymers, a process for producing functionalized polymers and the use of functionalized polymers, especially in the field of personal care.
Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
January 9, 2024
Assignee:
BLAZE BIOSCIENCE, INC.
Inventors:
Natalie Winblade Nairn, Julia Novak, Kenneth Grabstein, Dennis Miller, Greg T. Hermanson, Scott R. Presnell, Mark Stroud
Abstract: Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimers disease and Parkinsons disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Abstract: A skin care composition that includes a combination of palmitoyl dipeptide-7, acetyl tetrapeptide-11, other optional skin ingredients, and a dermatologically acceptable carrier. The combination of peptides synergistically improves cellular ATP level and/or upregulates the expression of peroxisome proliferator activated receptor alpha and/or methylsterol monooxygenase 1 to help provide improved skin health and appearance.
Type:
Grant
Filed:
January 4, 2023
Date of Patent:
December 26, 2023
Assignee:
The Procter & Gamble Company
Inventors:
Leo Timothy Laughlin, II, Michael Joseph Flagler, Lisa Ann Mullins, Makio Tamura
Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
Type:
Grant
Filed:
October 5, 2021
Date of Patent:
November 21, 2023
Assignee:
Eli Lilly and Company
Inventors:
Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NOs: 1-25], or a variant thereof, are described.
Type:
Grant
Filed:
November 1, 2022
Date of Patent:
November 21, 2023
Assignee:
Ohio University
Inventors:
Justin M. Holub, John J. Kopchick, Reetobrata Basu
Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
November 14, 2023
Assignee:
Ra Pharmaceuticals, Inc.
Inventors:
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
October 17, 2023
Assignee:
EDIX SA
Inventors:
Maria Isabel Gonzalez Garcia, José Maria Roca Torrellas, Tabatha Bourgois, Laurence Lachamp, Frederic Lacombe
Abstract: Methods for the synthesis of arginine-containing peptides are provided. The methods include a deprotection step that minimizes the transfer of by-products deriving from cleaved sulfonyl-5 based side chain protecting groups from arginine to amino acids carrying electron rich side chains.